A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of lebrikizumab [MILR1444A] in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma.

Trial Profile

A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of lebrikizumab [MILR1444A] in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma.

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Nov 2014

At a glance

  • Drugs Lebrikizumab (Primary)
  • Indications Airway obstruction; Allergic asthma
  • Focus Therapeutic Use
  • Sponsors Genentech
  • Most Recent Events

    • 07 May 2010 Actual end date (Nov 2009) added as reported by ClinicalTrials.gov.
    • 07 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 26 Aug 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top